Phio Pharmaceuticals to present Phase 1b trial data at SITC
What it means
- What to watch: Policy moves the whole healthcare aisle; trial data moves one company. Knowing which kind of story this is helps.
- How the stock is trading: $PHIO -1.53% in the latest session.
- Timing: It came out pre-market, so the next session was the first that could react.
Where the stock stands
$PHIO last traded at $0.79, -1.53% on the session. That puts it 58% shy of its 52-week high of $1.88 and 5.0% clear of its low of $0.75 — within a tenth of its 52-week low. Over the year it has ranged 151% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $PHIO page.
How much coverage it is getting
Wook has logged 2 stories on $PHIO in the last 30 days, 2 of them this week. At its 30-day pace you would expect less than one a week, so this week is running well ahead of normal — something has the newsroom's attention. Across those stories 0 read bullish, 2 neutral and 0 bearish. This one reads neutral, so it sits squarely with the crowd. This is the only one from Investing.com; the rest came from other outlets. 12 related stories from the same name or desk are listed beside this one.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. On Wook's supply-chain scanner, Health Care reads watch today — early signs of strain worth keeping an eye on.
Coming up
$PHIO earnings in 6 days. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the hard numbers get the last word soon.
What to watch next
For the receipts, the $PHIO page has the full chart, the filings and the valuation model these figures come from. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $PHIO is from its high, or how this week's coverage compares.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $PHIO. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 6, 2026. $PHIO has moved -1.62% ($0.80 to $0.79). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.